parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.09 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in distal convoluted tubule cells	0.75
chemistry Open Targets	hard to drug	0.24
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	9 Parkinson's papers of 70	0.70
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3012

receipt 3022: USP24 in dopamine neurons, braak

power: full sample +0.06 (p 0.814, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.840, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.19, sign flips 2; without severely affected donors +0.06 (p 0.814, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP24 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3021: USP24 in oligodendrocytes, braak

power: full sample +0.40 (p 0.099, n 18), 95% CI -0.08 to +0.73. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.46 (p 0.054, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.46 (p 0.054, n 18). could be the mix.
skeptic: leave-one-out range +0.32 to +0.55, sign flips 0; without severely affected donors +0.40 (p 0.099, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP24 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts